Research Article

Correlation between Prognostic Factors and the Histopathological Response to Neoadjuvant Chemotherapy in Osteosarcoma: A Retrospective Study

Table 2

Univariate analysis of clinical features and laboratory parameters with histopathological response based on Huvos grading system.

FeaturesHuvos response
PoorGoodCI 95%
n%n%RRminMax

SexMale2870.01230.00.1100.8000.6211.030
Female2187.5312.5

Age>20 years1593.816.20.0891.3241.0611.651
≤20 years3470.81429.2

Length of complaint>12 weeks4085.1714.90.0161.4611.0112.556
≤12 weeks952.9847.1

Tumor siteDistal3378.6921.40.6001.0800.8001.459
Proximal1672.7627.3

Tumor size (in diameter)≥10 cm4182.0918.00.0751.4350.8952.300
<10 cm857.1642.9

Postneoadjuvant chemotherapy tumor sizeEnlarged4588.2611.8<0.0012.8681.2616.521
Shrunk430.8969.2

StagingIII1894.715.30.0281.3751.1001.719
IIB3168.91431.1

MetastasisPresent1894.715.30.0281.3751.1001.719
Not identified3168.91431.1

Pathological fracturePresent6100.000.00.3221.3491.1591.570
Not identified4374.11513.6

Preneoadjuvant chemotherapy ALP serum levelIncreased2482.8517.20.5781.0730.8401.371
Normal2777.1822.9

Preneoadjuvant chemotherapy LDH serum levelIncreased5079.41320.61.0000.7940.7000.900
Normal1100.000.0

Postneoadjuvant chemotherapy ALP serum levelIncreased1979.2520.80.7031.0560.8041.386
Normal3075.01025.0

Increase in postneoadjuvant chemotherapy ALP serum levelIncreased1890.0210.00.1171.2771.0041.625
Decreased3170.51329.5

Postneoadjuvant chemotherapy LDH serum levelIncreased4876.21523.81.0007620.6640.875
Normal1100.000.0

Increase in postneoadjuvant chemotherapy LDH serum levelIncreased2678.8721.20.3381.1458651.515
Decreased2271.0929.0

Neoadjuvant chemotherapy number of cycles<2 cycles480.0120.01.0001.0490.6621.663
≥2 cycles4576.31423.7

Interval towards surgery postneoadjuvant chemotherapy>4 weeks2725.367.70.3061.1530.8741.520
≤4 weeks2271.0929.0

Surgical procedureAblation2177.8622.20.8451.0280.7831.349
Salvage2875.7924.3